Retinalgenix Technologies (ID)【RTGN】銘柄情報

Retinalgenix Technologies Inc (ID) (RTGN) 銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

通貨

4.00

( - )

買値

1.40

売値

4.00

出来高

平均取引量 (3 か月)

US$ 500

財務取引量

0.00 日の範囲 0.00

3.20 52 週間の範囲 4.01

時価総額

75.019M

企業価値

75.074M

前日終値

4.00

始値

時刻

最終取引時間

VWAP

歳入

純利益

-2.43M

発行済株式数

18,754,739

浮動株比率 (%)

33.27%

機関投資家保有比率 (%)

配当利回り

PER

-30.63

株価売上高倍率 (PSR)

1 株当たり利益 (EPS)

-0.13

ベータ

-3.33

RetinalGeniX Technologies Inc., an ophthalmic research and development company, focuses on developing technologies to screen, monitor, diagnose, and treat ophthalmic, optical, and sight-threatening disorders. The company offers the Retinal Imaging Screening Device, a portable retinal imaging system ... RetinalGeniX Technologies Inc., an ophthalmic research and development company, focuses on developing technologies to screen, monitor, diagnose, and treat ophthalmic, optical, and sight-threatening disorders. The company offers the Retinal Imaging Screening Device, a portable retinal imaging system providing a wide field of view without requiring pupil dilation; and RetinalCam, an in-home/remote location patient-activated monitoring and imaging device offering real-time communication and alerting system for physicians. It also develops RTG-2023 for the treatment of dry age-related macular degeneration; and RTG-2024 for the treatment of Alzheimer’s syndrome dementia. The company was incorporated in 2017 and is based in Apollo Beach, Florida. RetinalGenix Technologies Inc. is a subsidiary of Sanovas Ophthalmology, LLC. 詳細を表示

セクター

Health Care

業界

Health Care Equipment & Supplies

ウェブサイト

retinalgenix.com

本社

Apollo Beach, United States

設立

2026

Retinalgenix Technologies Inc (ID) is listed in the Health Care sector of the その他OTC with ticker RTGN. The last closing price for Retinalgenix Technologies (ID) was US$4. Over the last year, Retinalgenix Technologies (ID) shares have traded in a share price range of US$ 3.20 to US$ 4.01.

Retinalgenix Technologies (ID) currently has 18,754,739 shares in issue. The market capitalisation of Retinalgenix Technologies (ID) is US$75.02 million. Retinalgenix Technologies (ID) has a price to earnings ratio (PE ratio) of -30.63.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB

Form 8-K - Current report

RetinalGenix Reports on its Science and Mission in Light of New AI-Driven Retinal Mapping Study

APOLLO BEACH, Fla., Jan. 14, 2026 (GLOBE NEWSWIRE) -- RetinalGenix Technologies Inc. [OTCQB: RTGN]...

RetinalGenix Technologies Agrees To Hire M. Cory Zwerling as CFO, Interim COO

APOLLO BEACH, Fla., Dec. 08, 2025 (GLOBE NEWSWIRE) -- RetinalGenix Technologies Inc. [OTCQB: RTGN]...

RetinalGenix Technologies Contracts with Seer Bio to Explore Early Detection of Neurodegenerative, Systemic, and Retinal Diseases

APOLLO BEACH, Fla., Oct. 16, 2025 (GLOBE NEWSWIRE) -- RetinalGenix Technologies Inc. [OTCQB: RTGN]...

RetinalGenix Technologies and RGEN Clinical Genotyping Laboratory Announce Strategic Collaboration to Advance Early Detection of Neurodegenerative, Systemic, and Retinal Diseases

APOLLO BEACH, Fla. and HUNTINGTON, W.Va., Oct. 01, 2025 (GLOBE NEWSWIRE) -- RetinalGenix Technologies Inc...

RetinalGenix Technologies Advances Home and Remote Monitoring Patent Portfolio, Positioning for the Future of Ocular and Systemic Disease Care

APOLLO BEACH, Fla., Sept. 25, 2025 (GLOBE NEWSWIRE) -- RetinalGenix Technologies Inc. (OTCQB:RTGN...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0.8	25	3.2	4	3.2	125	4	CS
26	0.8	25	3.2	4	3.2	83	4	CS
52	0.46	12.9943502825	3.54	4.01	3.2	1183	3.81199272	CS
156	1	33.3333333333	3	6.36	0.25	766	3.79117779	CS
260	1	33.3333333333	3	20	0.25	582	4.12727898	CS